The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Regulatory News (SENS)

  • There is currently no data for SENS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Change of Registered Office

2 Oct 2018 07:00

RNS Number : 6143C
Sensyne Health PLC
02 October 2018
 

 

 

 

PRESS RELEASE

Sensyne Health plc

 

Change of registered office address

 

Oxford, UK; 01 October 2018: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, today announces that it has changed its registered address with immediate effect to:

 

Schrödinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE.

 

 

 

-ENDS-

 

For more information please contact:

 

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer

Lorimer Headley, Chief Financial Officer

Laura Steward, Head of Marketing

Peel Hunt LLP (Nominated Adviser and Broker)

+ 44 (0) 20 7418 8900

Dr Christopher Golden

James Steel

Oliver Jackson

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott

Sukaina Virji

Melissa Gardiner

sensynehealth@consilium-comms.com

 

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles and code of conduct, UK data protection law and applicable regulatory guidance.

 

Sensyne Health is quoted on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CROBFLLBVBFLFBV
Date   Source Headline
3rd Nov 20213:00 pmBUSForm 8.3 - SENS LN
3rd Nov 20212:10 pmRNSForm 8.3 - Sensyne Health plc
3rd Nov 20211:54 pmRNSForm 8.3 - Sensyne Health Plc
3rd Nov 20211:10 pmRNSForm 8.3 - Sensyne Health Plc
3rd Nov 202112:58 pmGNWInvesco Ltd.: Form 8 (OPD) - Sensyne Health PLC
3rd Nov 202112:08 pmRNSHolding(s) in Company
3rd Nov 202112:00 pmRNSForm 8.5 (EPT/RI) - Sensyne Health Plc
3rd Nov 20219:51 amRNSForm 8.5 (EPT/RI)
3rd Nov 20218:23 amRNSForm 8.3 - Sensyne Health Plc
2nd Nov 20213:02 pmGNWForm 8.3 - Octopus Investments - Sensyne Health plc
2nd Nov 20217:00 amRNSStrategic update, FSP triggered by potential MBO
29th Oct 20215:04 pmRNSResults of Annual General Meeting
21st Oct 20217:00 amRNSMagnifEye European regulatory certification
15th Oct 20217:00 amRNSSensyne and OMNY Health Sign Teaming Agreement
6th Oct 20217:00 amRNSHoldings in Company
6th Oct 20217:00 amRNSAnnual Report and Accounts
4th Oct 20212:05 pmRNSSecond Price Monitoring Extn
4th Oct 20212:00 pmRNSPrice Monitoring Extension
1st Oct 20217:00 amRNSSensyne Health 2021 Financial Results
24th Sep 20217:00 amRNSNotice of Preliminary Results
9th Sep 20217:00 amRNSLaunch of SENSIGHT data analytics platform
2nd Sep 20217:00 amRNSSensyne & GOSH partner in child disease research
19th Aug 20217:00 amRNSSensyne SRA With Sentara Healthcare
10th Aug 20217:00 amRNSSensyne announces AI drug discovery project
2nd Aug 20217:01 amRNSBoard Change
2nd Aug 20217:00 amRNSSensyne dataset reaches 60m patients
22nd Jul 20217:00 amRNSAppointment of Chief Scientific Officer
19th Jul 20217:00 amRNSSensyne Health Provides Strategic Update
18th Jun 20217:00 amRNSNED Appointment
17th Jun 20213:02 pmRNSHolding(s) in Company
1st Jun 20217:00 amRNSMagnifEye Production Contract with UK DHSC
28th May 20212:24 pmRNSShare Option Award
27th May 20217:00 amRNSTrading Update
25th May 20211:13 pmRNSHolding(s) in Company
24th May 20217:00 amRNSSRA with Colorado Center for Personalized Medicine
21st May 20219:14 amRNSPharmaceutical collaboration
21st May 20217:00 amRNSSensyne signs SRA with St. Luke’s
7th May 202111:12 amRNSHolding(s) in Company
7th May 20217:00 amRNSMagnifEye Gains MHRA Approval
6th May 20217:00 amRNSValue Creation Plan Award
30th Apr 20217:00 amRNSSensyne SRA with Royal Devon and Exeter NHS Trust
16th Apr 20217:00 amRNSIssue of Shares and Total Voting Rights
12th Mar 20217:00 amRNSAgreement with the UK DHSC
1st Mar 20217:00 amRNSBoard Changes
1st Mar 20217:00 amRNSSYNE-COV Achieves UK Regulatory Approval
10th Feb 20212:06 pmRNSSecond Price Monitoring Extn
10th Feb 20212:00 pmRNSPrice Monitoring Extension
9th Feb 20217:48 amRNSSensyne licenses MagnifEye technology to Excalibur
5th Feb 20212:57 pmRNSHoldings in Company
5th Feb 20212:24 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.